Esperion Therapeutics (ESPR) Tops Q4 EPS by 9c

Esperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of ($0.76), $0.09 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $18.18 million versus the consensus estimate of $20.57 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Deere shares climb as fiscal Q3 earnings and revenue top estimates
• Bernstein upgrades Analog Devices on Q3 beat, improving risk-reward